July 18, 2014

Blood Biomarkers to Guide Surveillance and Treatment of Uveal Melanoma Being Explored

New options being explored may one day improve outcomes

690×380-Blood-Biomarkers

By Arun D. Singh, MD, Cleveland Clinic Cole Eye Institute ocular oncologist

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Overall mortality in uveal melanoma is high due to metastatic disease that develops despite advances in its diagnosis and improvements in local tumor control. Several lines of evidence indicate that micrometastases are present in many patients with uveal melanoma at the time of ophthalmic diagnosis. In partnership with Pierre Triozzi, MD, of the Taussig Cancer Institute, we have explored new options to treating this challenging disease. An effective strategy to improve survival in uveal melanoma would be to identify patients with micrometastases and suppress those micrometastases before they progress to macrometastases. Chromosomal aberrations (monosomy-3 and others) and gene expression profiling of tumors are superior to clinical and histopathological factors in predicting metastasis.

Fine-needle aspiration biopsy of tumors at the time of local therapy (plaque radiation), tumor resection and enucleation are the methods applied to obtain material for molecular prognostication. The time from diagnosis of the primary tumor to discovery of metastasis can range from weeks to decades. Assessment of tumor tissue, however, does not indicate whether tumor cells have actually been shed or are forming metastasis, and whether adjuvant treatment is reducing micrometastasis.

Early biomarkers of micrometastases needed

The identification and validation of blood biomarkers may permit early detection of uveal melanoma metastasis and could potentially allow for adoption of effective strategies to suppress micrometastases before they progress, thereby improving prognosis. Cole Eye Institute is actively exploring the utility of immune regulation factors in the blood and other new blood biomarkers in an effort to better define prognosis and monitor disease progression in patients with uveal melanoma.

Advertisement

Detection of circulating melanoma cells is a convenient test that may be potentially useful for diagnosis, risk stratification, identification of metastasis and treatment monitoring in uveal melanoma. The results of polymerase chain reaction-based and immunomagnetic techniques tested to date are controversial and cannot be interpreted reliably.

A variety of blood constituents, ranging from melanoma-associated mRNA, vascular endothelial growth factor, hepatocyte growth factor, epidermal growth factor and insulin-like growth factor-1 (IGF-1) have been implicated in progression of uveal melanoma and are measurable in patient serum or in experimental models of uveal melanoma. For various biological and technical reasons, these biomarkers have not demonstrated to date the sensitivity, specificity and predictive values necessary to monitor metastasis in patients with uveal melanoma.

A possible prognostic role for B2M

Beta2-microglobulin (B2M) is a component of the HLA class I molecule light chain. Like the HLA class I heavy chain, tumor B2M expression by immunohistochemistry has been associated with metastasis in uveal melanoma. Because it is noncovalently associated, B2M can circulate. We studied 76 patients, 47 treated by plaque brachytherapy and 29 treated by enucleation. Thirty-three (43 percent) of the tumors manifested monosomy-3. Most tumors were large, were located in the choroid and were of mixed cell type. Blood was drawn in patients without metastatic disease prior to fine-needle aspiration biopsy. Tumor chromosome 3 status was determined by fluorescence in situ hybridization. Levels of B2M, IGF-1 and insulin-like growth factor-binding protein-3 (IGFBP-3) were determined by enzyme-linked immunosorbent assays. Blood levels of IGF-1 and IGFBP-3 were not associated with tumor monosomy-3. In contrast, increases in blood B2M (p ≤ 0.02) were.

Advertisement

The independent association of increased blood level of B2M and tumor monosomy-3 status was confirmed in multivariable analysis. Measuring blood levels of B2M in patients with primary uveal melanoma may therefore have prognostic value and may help guide surveillance and adjuvant therapy recommendations.

For more information, contact Dr. Singh at ophthalmologyupdate@ccf.org.

Related Articles

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Ad